Elimination of intravenous oxycodone in the elderly: A pharmacokinetic study in postoperative orthopaedic patients of different age groups

Drugs and Aging

Volumn 28, Issue 1, 2011, Pages 41-50

  Liukas, Antti ^a   Kuusniemi, Kristiina ^a   Aantaa, Riku ^a   Virolainen, Petri ^a   Neuvonen, Mikko ^b   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Analgesia; Elderly; Opioid analgesics, pharmacokinetics; Oxycodone, pharmacokinetics.

Indexed keywords

CREATININE; CYTOCHROME P450 2D6; DRUG METABOLITE; GLYCOPYRRONIUM BROMIDE; NALOXONE; NOROXYCODONE; NOROXYMORPHONE; ONDANSETRON; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRADYCARDIA; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOPEDIC SURGERY; OXYGEN DESATURATION; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; SEX DIFFERENCE; SIDE EFFECT; STEADY STATE; TANDEM MASS SPECTROMETRY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CREATININE; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHINANS; ORTHOPEDIC PROCEDURES; OXYCODONE; OXYMORPHONE; PAIN, POSTOPERATIVE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 78650674116     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11586140-000000000-00000     Document Type: Article

References (24)

1. Kalso E, Pöyhiä R, Onnela P, et al. Oxycodone and morphine in postoperative pain. Acta Anaesthesiol Scand 1991; 35: 642-6
2. Saari TI, Grönlund J, Hagelberg NM, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010; 66: 387-97
3. PöyhiäR, Seppälä T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992:33: 617-21
4. Leow KP, SmithMT,Watt JA, et al. Comparative oxycodone pharmacokinetics in humans after intravenous, oral and rectal administration. Ther DrugMonit 1992; 14: 479-84
5. Leow KP, Smith M, Williams BE, et al. Single dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52: 487-95
6. Paulozzi LJ. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health 2006; 96: 1755-7
7. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998; 64: 603-11
8. Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79: 461-79
9. El-Tahtawy A, Kokki H, Reidenberg BE. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. J Clin Pharmacol 2006; 46: 433-42
10. Kokki H, Rasanen I, Reinikainen M, et al. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 2004; 43: 613-22
11. Olkkola KT, Hamunen K, SeppäläT, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38: 71-6
12. Pokela M-L, Anttila E, SeppäläT, et al. Marked variation in oxycodone pharmacokinetics in infants. Pediatr Anesth 2005; 15: 560-5
13. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007; 82: 87-96
14. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47
15. Neuvonen M, Neuvonen PJ. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography- electrospray-tandem mass spectrometry. Ther DrugMonit 2008; 30: 333-40
16. Sistonen J, Fuselli S, Levo A, et al. CYP2D6 genotyping by a multiplex primer extension reaction. Clin Chem 2005; 51: 1291-5
17. Liukas A, Kuusniemi K, Aantaa R, et al. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 2008; 84: 462-7
18. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76
19. Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008; 64: 183-99
20. KirveläM, Lindgren L, SeppäläT, et al. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8: 13-8
21. Kaiko R, Benziger D, Cheng C, et al. Clinical pharmacokinetics of controlled release oxycodone in renal impairment [abstract]. Clin Pharmacol Ther 1996; 59: 130
22. Purdue Pharma prescribing information on Oxycontin (oxycodone HCl controlled-release) tablets [online]. Available from URL: http://www. purduepharma.com/PI/Prescription/Oxycontin.pdf [Accessed 2010 Apr 21]
23. Zwisler ST, Enggaard TP, Mikkelsen S, et al. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010; 54: 232-40
24. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 631-46